Last reviewed · How we verify
NCT06788119
Analyzing the Benefits of Using SYMPTOMS-JIT for in Vivo Exposure in Anxiety Disorders
NA trial testing Cognitive behavioral therapy with in vivo exposure in Anxiety Disorders in 158 participants. Currently enrolling.
30 June 2027
Quick facts
| Lead sponsor | Universitat Jaume I |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 158 |
| Start date | 30 April 2025 |
| Primary completion | 30 June 2027 |
| Estimated completion | 31 December 2027 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Cognitive behavioral therapy with in vivo exposure
- Cognitive behavorial therapy with in vivo exposure plus SYMPTOMS-JIT
Conditions studied
- Anxiety Disorders — all drugs for Anxiety Disorders →
- Specific Phobia — all drugs for Specific Phobia →
- Panic Disorder — all drugs for Panic Disorder →
- Agoraphobia — all drugs for Agoraphobia →
Sponsor
Universitat Jaume I — full company profile →
Who can join
18 and older, any sex, with Anxiety Disorders or Specific Phobia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to develop and test the efficacy of first-of-its-kind, fully instrumented sensor-based smartphone-guided in-vivo exposure therapy using a just-in-time intervention for anxiety disorder. The main hypotheses are: 1. Both treatment conditions (CBT treatment with IVE and CBT treatment with IVE+SYMPTOMS-JIT) will show efficacy and no statistically significant differences will be found between them. The efficacy will be determined for the differences in pre-post treatment in the used outcome measures. 2. The therapeutic gains obtained in both treatment conditions (IVE and (IVE+SYMPTOMS-JIT) will be maintained at 1-, 6-, and 12-month follow-up periods. 3. Both treatment conditions will be efficient, that is, they will be well-valued by patients and therapists. However, IVE+SYMPTOMS-JIT will be preferred and perceived as less aversive than IVE. 4. The main barriers for the use of this technology are not technological, but rather attitudinal and they can be identified through qualitative studies.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06788119
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Anxiety Disorders
Currently open trials in the same condition.
- NCT07340281 — Biomarkers for Exercise · NA · recruiting
- NCT07432945 — In Vivo Exposure vs. Videochat-Based Vicarious Exposure · NA · recruiting
- NCT07316374 — AI Chatbots for Anxiety Mental Health Literacy · NA · active not recruiting
- NCT07123467 — Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder · Phase 3 · recruiting
- NCT07174947 — SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depre · Phase 2 · recruiting
Other Universitat Jaume I trials
Trials by the same sponsor.
- NCT07202975 — RE-SCALE: Rehabilitation Engagement and Scaled Access With eXtended Reality and Artificial Intelligence · NA · not yet recruiting
- NCT07345117 — Cost-effectiveness and Implementation of a Transdiagnostic Internet-based Intervention for Emotional Disorders in Commun · NA · not yet recruiting
- NCT06932120 — Technology-supported Interventions for Prolonged Grief Disorder (PGD) · NA · recruiting
- NCT06839573 — Effectiveness of Immersive Virtual Reality in Nursing Students' Learning · NA · not yet recruiting
- NCT06969898 — Penyagolosa Trail Saludable 2025 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06788119 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universitat Jaume I
- Last refreshed: 16 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06788119.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing